Rani Therapeutics Holdings (RANI) Change in Receivables (2025)
Rani Therapeutics Holdings' (RANI) quarterly Change in Receivables came in at $2.5 million in Q4 2025, up 340.27% quarter-over-quarter from -$1.0 million in Q2 2025.
Rani Therapeutics Holdings (RANI) Change in Receivables (2025) Analysis & Trends
Rani Therapeutics Holdings' Change in Receivables history runs 1 years deep, the most recent figure standing at $2.5 million for Q4 2025.
- On a quarterly basis, Change in Receivables changed N/A year-over-year to $2.5 million in Q4 2025; TTM through Mar 2026 was $1.4 million, a 140.33% increase from a year earlier, with the FY2025 full-year figure at $2.0 million, changed N/A from the prior year.
- Change in Receivables rose to $2.5 million in Q4 2025 per RANI's latest filing, from -$1.0 million in the prior quarter.
- Across five years, Change in Receivables topped out at $2.5 million in Q4 2025 and bottomed at -$1.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 75.30 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 2.84 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -39.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -1.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Rani Therapeutics Holdings | 160.20 Mn | 167.33 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.47 Mn |
| Dec 31, 2025 | 2.47 Mn |
| Jun 30, 2025 | -1.03 Mn |
| Jun 30, 2025 | -1.03 Mn |
| Mar 31, 2025 | 600,000.00 |
| Mar 31, 2025 | 600,000.00 |